ArticleComputational and structural biotechnology journal2026
MiracleNet: A Biologically Interpretable Machine Learning Model for Resected Non-small-cell Lung Cancer.
Article in Computational and structural biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains one of the leading causes of cancer-related mortality worldwide. Accurate prediction of relapse is notoriously difficult, posing substantial challenges to patient care and necessitating advanced tools to improve prognostic outcomes. MicroRNA (miRNA) expression profiles hold promise as biomarkers for predicting relapse, yet existing predictive models lack interpretability or sufficient predictive performance. Biologically informed neural networks have emerged as a modeling approach incorporating biological interpretability and predictive accuracy. Here, we introduce MiracleNet, to our knowledge the first visible neural network in which sparse connectivity is structured by the miRNA → target gene → pathway hierarchy for disease-free survival prediction from circulating miRNA in non-small-cell lung cancer and the first to expose interpretable importances jointly at all 3 biological layers, with nodes connected by prior knowledge about miRNA targets and related biological pathways. Our model, which also integrates clinical data, achieves a maximum concordance index of 0.76, demonstrates improved generalization over unconstrained neural networks of the same dimensionality (including both dense and sparse architectures lacking biological knowledge), and provides explicit biological interpretability. Our model also highlights several important biomarkers in the form of predictive miRNAs and connected biological pathways. We additionally evaluate MiracleNet under a nested repeated 80/20 protocol, augmented with patient sex and tumor stage as clinical covariates and combined across circulating free and extracellular-vesicle-associated miRNAs through early and intermediate fusion; these analyses are reported as separate sections.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.